JUBLPHARMA.BOJUBLPHARMA.BOBSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +8.62% | +9.68% | +9.76% | +12.22% | +16.51% |
| Gross Profit Growth | +9.30% | +6.21% | +9.62% | -47.48% | -53.57% |
| EBITDA Growth | +37.87% | +27.84% | +10.68% | +19.49% | +2.52% |
| Operating Income Growth | +22.78% | +6.06% | +12.04% | -62.63% | -75.44% |
| Net Income Growth | +51.05% | +0.00% | -78.66% | +17.02% | -44.60% |
| EPS Growth | +50.95% | +0.00% | -78.68% | +17.31% | -44.58% |
| EPS Diluted Growth | +51.43% | +0.00% | -78.68% | +17.18% | -44.50% |
| Weighted Average Shares Growth | -0.25% | -0.23% | +0.12% | -0.46% | -0.16% |
| Weighted Average Shares Diluted Growth | -0.25% | -0.08% | +0.12% | -0.14% | -0.16% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -28.64% | +0.00% | +20.99% | +0.00% |
| Inventory Growth | +0.00% | -12.44% | +0.00% | +5.76% | +0.00% |
| Asset Growth | +0.00% | +10.46% | +0.00% | +13.39% | +0.00% |
| Book Value per Share Growth | +10.01% | +15.37% | +14.94% | +11.47% | +0.00% |
| Debt Growth | +0.00% | -25.46% | +0.00% | -6.41% | +0.00% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -3.68% | +6.31% | +6.91% | -30.48% | -26.75% |